How does the metabolism of tumour cells differ from that of normal cells

Tumour cells thrive in environments that would be hostile to their normal cell counterparts. Survival depends on the selection of cell lines that harbour modifications of both, gene regulation that shifts the balance between the cell cycle and apoptosis and those that involve the plasticity of the metabolic machinery. With regards to metabolism, the selected phenotypes usually display enhanced anaerobic glycolysis even in the presence of oxygen, the so-called Warburg effect, and anabolic pathways that provide precursors for the synthesis of lipids, proteins and DNA. The review will discuss the original ideas of Otto Warburg and how they initially led to the notion that mitochondria of tumour cells were dysfunctional. Data will be presented to show that not only the organelles are viable and respiring, but that they are key players in tumorigenesis and metastasis. Likewise, interconnecting pathways that stand out in the tumour phenotype and that require intact mitochondria such as glutaminolysis will be addressed. Furthermore, comments will be made as to how the peculiarities of the biochemistry of tumour cells renders them amenable to new forms of treatment by highlighting possible targets for inhibitors. In this respect, a case study describing the effect of a metabolite analogue, the alkylating agent 3BP (3-bromopyruvate), on glycolytic enzyme targets will be presented.

[1]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[2]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[3]  A. Goffeau,et al.  Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae , 2012, Journal of Bioenergetics and Biomembranes.

[4]  Jesse M. Platt,et al.  Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability , 2011, Proceedings of the National Academy of Sciences.

[5]  B. Van Houten,et al.  Metabolic symbiosis in cancer: Refocusing the Warburg lens , 2013, Molecular carcinogenesis.

[6]  G. Semenza HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[7]  R. Rossignol,et al.  Mitoplasticity: adaptation biology of the mitochondrion to the cellular redox state in physiology and carcinogenesis. , 2013, Antioxidants & redox signaling.

[8]  Saroj P. Mathupala,et al.  Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.

[9]  A. Cassago,et al.  Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism , 2012, Proceedings of the National Academy of Sciences.

[10]  A. Goffeau,et al.  Yeast ATP-binding cassette transporters conferring multidrug resistance. , 2012, Annual review of microbiology.

[11]  D. Tang,et al.  PKM2, a Central Point of Regulation in Cancer Metabolism , 2013, International journal of cell biology.

[12]  P. Vaupel,et al.  Availability, not respiratory capacity governs oxygen consumption of solid tumors. , 2012, The international journal of biochemistry & cell biology.

[13]  A. Galina,et al.  Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. , 2009, The Biochemical journal.

[14]  A. Levine,et al.  Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function , 2010, Proceedings of the National Academy of Sciences.

[15]  J. Neuzil,et al.  Mitochondrial complex II, a novel target for anti-cancer agents. , 2013, Biochimica et biophysica acta.

[16]  T. Soga Cancer metabolism: Key players in metabolic reprogramming , 2013, Cancer science.

[17]  Saroj P. Mathupala,et al.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. , 2009, Seminars in cancer biology.

[18]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[19]  W. Kaelin New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. , 2010, Annals of the New York Academy of Sciences.

[20]  Juliana Camacho-Pereira,et al.  3-Bromopyruvate inhibits calcium uptake by sarcoplasmic reticulum vesicles but not SERCA ATP hydrolysis activity. , 2012, The international journal of biochemistry & cell biology.

[21]  J. Matés,et al.  New insights into brain glutaminases: Beyond their role on glutamatergic transmission , 2009, Neurochemistry International.

[22]  M. Shoshan Potentiation of anti-cancer treatment by modulators of energy metabolism. , 2013, Current pharmaceutical biotechnology.

[23]  Emma Saavedra,et al.  Energy metabolism in tumor cells , 2007, The FEBS journal.

[24]  D. Sabatini,et al.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.

[25]  Gregory Stephanopoulos,et al.  Quantifying Reductive Carboxylation Flux of Glutamine to Lipid in a Brown Adipocyte Cell Line* , 2008, Journal of Biological Chemistry.

[26]  Jose Russo,et al.  Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. , 2012, Biochimica et biophysica acta.

[27]  E. Chen Mitochondrial dysfunction and cancer metastasis , 2012, Journal of Bioenergetics and Biomembranes.

[28]  M. Brand,et al.  Assessing mitochondrial dysfunction in cells , 2011, The Biochemical journal.

[29]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[30]  J. Hayashi,et al.  Regulation of metastasis; mitochondrial DNA mutations have appeared on stage , 2012, Journal of Bioenergetics and Biomembranes.

[31]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[32]  T. Reid,et al.  The scarlet letter of alkylation: a mini review of selective alkylating agents. , 2012, Translational oncology.

[33]  E. M. Smith,et al.  Molecular cloning of a cDNA for rat hepatic glutaminase. Sequence similarity to kidney-type glutaminase. , 1990, The Journal of biological chemistry.

[34]  P. Pedersen,et al.  Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. , 2001, Cancer letters.

[35]  K. Vousden Alternative fuel—another role for p53 in the regulation of metabolism , 2010, Proceedings of the National Academy of Sciences.

[36]  Eva M. Schmelz,et al.  Metabolic changes during ovarian cancer progression as targets for sphingosine treatment. , 2013, Experimental cell research.

[37]  Martin G Pomper,et al.  Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.

[38]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[39]  L. Neckers,et al.  Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis , 2013, Proceedings of the National Academy of Sciences.

[40]  A. Galina,et al.  Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase , 2012, Journal of Bioenergetics and Biomembranes.

[41]  R. Curi,et al.  Glutamine, gene expression, and cell function. , 2007, Frontiers in bioscience : a journal and virtual library.

[42]  A. Goffeau Drug resistance: The fight against fungi , 2008, Nature.

[43]  G. Semenza Regulation of metabolism by hypoxia-inducible factor 1. , 2011, Cold Spring Harbor symposia on quantitative biology.

[44]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[45]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[46]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[47]  V. Ganapathy,et al.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. , 2009, Pharmacology & therapeutics.

[48]  F. Sotgia,et al.  Mitochondrial metabolism in cancer metastasis , 2012, Cell cycle.